Kinnate Biopharma Investor Presentation — August 2022

Document content

A Clinical- Stage Precision Oncology Company

Corporate Presentation

August 2022Thispresentation (including theaccompanying oral presentation) contains forward -looking statements that involve substantial risks and uncertainties .Allstatements other than statements of

historical facts contained inthispresentation, including statements regarding thefuture financial condition, results ofoperations, business strategy and plans, and objectives ofmanagement

forfuture operations ofKinnate Biopharma Inc.("we," "us"or"our"), aswell asstatements regarding industry trends, areforward -looking statements .Insome cases, you can identify forward -

looking statements byterminology such as“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially” “predict,” “should,” “will” orthenegative

ofthese terms orother similar expressions. Wehave based these forward -looking statements largely onourcurrent expectations and projections about future events and trends that we

believe may affect ourfinancial condition, results ofoperations, business strategy and financial needs .

These forward -looking statements aresubject toanumber ofrisks, uncertainties and assumptions, including, among other things: ourability tosuccessfully complete ourongoing clinical trials

and forthose trials toproduce positive results, ourestimates ofthenumber ofpatients who suffer from thediseases wearetargeting and thenumber ofpatients that may enroll inourclinical

trials ;ourability tofileINDs inthefuture ;thecommercializing ofourproduct candidates, ifapproved ;thetiming oftheinitiation, progress and potential results ofourongoing and planned

preclinical studies and clinical trials and ourresearch programs ;ourability toadvance additional product candidates into, and successfully complete, preclinical studies and clinical trials with

those additional product candidates ;thetiming orlikelihood ofregulatory filings and approvals ;ourproduct development and marketing strategy; thenegative impacts oftheCOVID -19

pandemic ;ourability and thepotential tosuccessfully manufacture and supply ourproduct candidates forclinical trials and forcommercial use, ifapproved ;future strategic arrangements

and/or collaborations and thepotential benefits ofsuch arrangements ;ourestimates regarding expenses, future revenue, capital requirements and needs forfinancing and ourability to

obtain capital ;thesufficiency ofourexisting cash and cash equivalents tofund ourfuture operating expenses and capital expenditure requirements ;ourability toretain thecontinued service

ofourkeypersonnel and toidentify, hireand retain additional qualified professionals ;theimplementation ofourbusiness model, strategic plans forourbusiness and product candidates ;the